ArticleResearch square2026
From Gestational Age-Specific Serum Creatinine Trajectories to an Interactive Clinical Interpretation Tool in Level IV NICU Infants.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Objective: To characterize gestational age (GA)-specific serum creatinine (SCr) trajectories among level IV neonatal intensive care unit (NICU) infants and develop an interactive interpretation tool. Study Design: We analyzed ADVANCE database records linking kidney-specific data with Children's Hospitals Neonatal Consortium clinical data from ten level IV NICUs (2010-2022). Infants with ≥ 1 SCr measurement (DOL 1-365) were included. GA-specific trajectories were generated for DOL 1-28 and week of life 1-16; an interactive tool was developed for clinical use. Result: Among 34,306 infants contributing 390,612 SCr measurements, SCr trajectories differed by GA. Peak SCr ranged from 0.93 mg/dL (IQR 0.80-1.10) at 22-24 weeks' GA (DOL 4) to 0.76 mg/dL (IQR 0.65-0.90) among term infants (DOL 2), declining to a similar nadir (~ 0.20-0.23 mg/dL) across GA groups. Conclusion: SCr trajectories vary by GA and postnatal age in this population. These trajectories and the accompanying tool provide context for interpreting SCr values.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.